Director/PDMR Shareholding

About this update from Ekf Diagnostics Holdings Plc

EKF Diagnostics Holdings plc ("EKF", the "Company" or the "Group")   PDMR/Director Dealings   EKF Diagnostics Holdings plc  (AIM: EKF), the AIM-listed global diagnostics business, announces that on Tuesday 25 March 2025, the following members of the EKF Board purchased 550,000 ordinary shares of 1 pence each in the Company (" Ordinary Shares ") at a price of 22.0 pence per Ordinary Share:       Director Title Number of Ordinary Shares purchased Resulting holding in Ordinary Shares Percentage of issued share capital Julian Baines Executive Chair 50,000 1,666,288 0.37% Gavin Jones Chief Executive Officer 50,000 50,000 0.01% Stephen Young Chief Financial Officer 50,000 135,000 0.03% Christopher Mills¹ Non-Executive Director 150,000 133,500,000  29.42% Christian Rigg Non-Executive Director 100,000 100,000 0.02% Jennifer Winter Non-Executive Director 150,000 150,000   0.03%   ¹Includes direct and indirect interests in the Company     EKF Diagnostics Holdings plc www.ekfdiagnostics.com Julian Baines, Executive Chair  Tel: +44 (0)29 2071 0570 Singer Capital Markets (Nominated Adviser & Broker) Tel: +44 (0)20 7496 3000 Phil Davies / Oliver Platts Walbrook PR Limited Tel: +44 (0)20 7933 8780 or [email protected] Paul McManus / Alice Woodings Mob: +44 (0)7980 541 893 / +44 (0)7407 804 654   About EKF Life Sciences   EKF Life Sciences is a specialist global manufacturer of high-quality enzymes and custom products for use in diagnostic, pharmaceutical, and industrial applications.   EKF Life Sciences is at the forefront of supporting global demand in precision fermentation, enzyme applications and research, providing innovative biotechnology solutions to deliver advancements in healthcare and medicine.   Utilising its unique technical expertise, the EKF Life Sciences uses precision microbial fermentation and advanced downstream processes to isolate and deliver the highest quality enzymes and biomolecules that have been specially engineered to customer specifications.   EKF Life Sciences has two state-of-the-art GMP manufacturing facilities, located within close proximity, in Elkhart and South Bend Indiana, one the US's major life sciences and industrial hotspots. It operates to the highest regulatory standards under cGMP principles, FDA certification and ISO 13485 Quality Program. The facilities include bioreactors ranging from 5L to 14,500L, enabling it to offer an end-to-end service from bench/proof-of-concept through to full scale commercial production, providing its customers with desired yields, precision at scale and cost-efficiency.   EKF Lifesciences is also one of the market leaders for the supply of β-HB, a reagent used to detect ketones for patients suffering from diabetic ketoacidosis, as well as many other clinical applications.   About EKF Diagnostics Holdings plc ( www.ekfdiagnostics.com )   EKF is an AIM-listed global diagnostics business focussed on:   ·    Point-of-Care analysers in the key areas of Hematology and Diabetes, as well as Central Laboratory products including clinical chemistry reagents, analysers and centrifuges.   ·      Life Sciences services provide specialist manufacture of enzymes and custom products for use in diagnostic, food and industrial applications, as well as other higher value Contract Manufacturing services. EKF has headquarters in Penarth (near Cardiff) and operates five manufacturing sites across the US and Germany, selling into over 120 countries world-wide.   Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them   1   Details of the person discharging managerial responsibilities / person closely associated   a)   Name     1.    Julian Baines 2.    Gavin Jones 3.    Stephen Young 4.    Christopher Mills 5.    Christian Rigg 6.    Jennifer Winter 2   Reason for the notification   a)   Position/status     1.    Executive Chair 2.    Chief Executive Officer 3.    Chief Financial Officer 4.    Non-Executive Director 5.    Non-Executive Director 6.    Non-Executive Director b)   Initial notification /Amendment   Initial Notification 3 Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor a) Name   EKF Diagnostics Holdings plc b)   LEI   213800DXTF3EAUK1AR05   4   Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted   a)   Description of the financial instrument, type of instrument Ordinary shares of 1 pence each Identification code GB0031509804   b)   Nature of the transaction     Purchase of Ordinary Shares c)   Price(s) and volume(s) Price(s) Volume(s) 1.    22p 1.    50,000 2.    22p 2.    50,000 3.    22p 3.    50,000 4.    22p 4.    150,000 5.    22p 5.    100,000 6.    22p 6.    150,000 d)   Aggregated information - Aggregated volume n/a - Price e)   Date of the transaction      25 March 2025 f)   Place of the transaction     London Stock Exchange, AIMX          

View stock analysis, news, and events for Ekf Diagnostics Holdings Plc